Newly acquired SmartCurve™ breast stabilization system improves mammogram comfort without compromising image quality, workflow or dose
The Dorothy Mangurian Comprehensive Women's Center at Holy Cross HealthPlex is the first in Broward County to offer the SmartCurve™ breast stabilization system, which is clinically proven to deliver a more comfortable mammogram without compromising image quality, workflow or dose.[i] This latest innovation is part of Holy Cross' ongoing commitment to superior breast cancer detection and has the potential to increase screening volume and compliance for the countless women who have reported avoiding regular mammograms due in large part to the fear of discomfort associated with breast compression.
The SmartCurve system is available exclusively with Hologic’s Genius™3D Mammography™ exam, which is currently in use by Holy Cross and detects more invasive cancers, reduces false positives, and is FDA approved as superior to conventional 2D mammography for all women, including those with dense breasts.[ii],[iii],[iv]
“We are committed to providing the care and technology the women in our community need to receive the best possible breast care,” said Patrick A. Taylor, MD, President and CEO of Holy Cross Hospital.
The SmartCurve system features a proprietary curved surface that mirrors the shape of a woman’s breast to reduce pinching and allow better distribution of force over the entire breast. In a recent clinical study comparing the SmartCurve breast stabilization system to traditional flat paddle compression, the SmartCurve system improved comfort in 93 percent of women who reported moderate to severe discomfort with standard compression.1 In addition, 95 percent of those surveyed would recommend facilities that use the system.1
“With this new technology, we are able to provide a more comfortable mammogram while maintaining clinical accuracy, which is key,” said Howard Rubinson, MD, Radiologist. “Mammograms play a critical role in the early detection of breast cancer and with the addition of the SmartCurve system, our goal is to decrease the pain and anxiety often associated with mammograms and, as a result, increase screening compliance.”
The GeniusÔ3D MammographyÔexam is only available on a Hologic®3D Mammography™system.
The exam consists of a 2D and 3D™image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D™image set. There are more than 4,000 Hologic 3D Mammography™ systems in use in the U.S., so women have convenient access to the Genius exam. To learn more about the Genius exam, visit http://www.Genius3DNearMe.com.
For more information about Holy Cross' breast health services, visit https://womens.holy-cross.com.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, SmartCurve, Genius, 3D and 3D Mammography and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
1. Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00119 Rev 003 (2017).
2. Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D mammograms acquired with the Hologic 3D Mammography system versus women receiving 2D FFDM mammograms only.
3. Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
4. U.S. Food & Drug Administration Premarket Approval (PMA). FDA.gov https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080003 accessed June 5, 2017.